Progress in gastric cancer chemotherapy and strategy.docVIP

 PAGE \* MERGEFORMAT 34 Progress in gastric cancer chemotherapy and strategy Keywords: gastric cancer; chemotherapy; strategy; evolution Gastric cancer is one of the most common malignancy and its prognosis is poor. Surgical complete resection of gastric cancer is still the most important means of cure. However, gastric cancer recurrence rate as high as 50% to 70%, 5-year survival rate of only 20% to 50%, so people have been looking outside the surgical treatment of gastric cancer, ways to improve the prognosis of patients with gastric cancer. Since the 20th century, 60 years since the chemotherapy began to be used gastric cancer, after chemotherapy and the program “one after another,” but postoperative adjuvant chemotherapy for gastric cancer is still unsatisfactory. New drugs and new treatment strategies appear to make the application of chemotherapy in gastric cancer the emergence of new opportunities. The Evolution of a gastric cancer chemotherapy 1.1 Progress in gastric cancer chemotherapy in early Gastric cancer chemotherapy began in the 20th century, 60 years, 5  Fu of the most thorough, but the effects of single drug application, and not satisfied with the overall response rate of up to 21% [1]. 70 years combined chemotherapy began to emerge, in which FAM (fluorouracil, adriamycin, mitomycin C) program is widely used. However, randomized controlled studies have shown that FAM, FA (5  Fu, adriamycin), single-agent treatment of stomach cancer three 5  Fu response rate and survival period Quewu significant difference between the [2]. Wils et al [3] found that FAMTX (fluorouracil, doxorubicin, cyclophosphamide) in response rate and median survival were superior to FAM. FAMTX in Europe and the United States had once as a standard program of chemotherapy. 80 years of CF can enhance the cytotoxicity of 5  Fu role has been positive, the reaction rate of 33% ~ 44%, to biochemical conditioning regimen based on